| Document |
Document Title |
|
WO/2005/095345A2 |
Compounds of Formula (1), and pharmaceutically acceptable forms thereof, are provided wherein the variables X, Y, Z, Al, R2, R3, R4, R5 and R6 are defined herein. Certain compounds of Formula 1 described herein which possess potent antiv...
|
|
WO/2005/089734A2 |
The novel salt creatine glycinate and compositions (dietary supplements, energy drinks and dietetic or pharmaceutical products) containing same are described.
|
|
WO/2005/085159A1 |
Inositol derivatives in accordance with the present invention are effective in significantly enhancing the transportation of various therapeutic molecules across a biological membrane, which may include the plasma membrane, nuclear membr...
|
|
WO/2005/080322A1 |
A novel fluorene characterized by having a fluorene skeleton to which a functional group such as a guanidino group is attached via a carbonyl group, or its salt. This compound has such an advantage as showing a high affinity particularly...
|
|
WO/2005/075413A1 |
The invention relates to a two-stage method for producing guanidinium salts of formula (1), wherein the substituents R have the designation cited in patent claim 1, and A- is a sulfonate, an alkyl or aryl sulfate, a hydrogen sulfate, a i...
|
|
WO/2005/075414A1 |
A compound represented by the following general formula (I) or a salt thereof. [Chemical formula 1] (I) (In the formula, R1, R2, and R3 each independently represents hydrogen or C1-3 alkyl, provided that at least one of R1, R2, and R3 is...
|
|
WO/2005/072121A2 |
Carboxylic acid-substituted polyalkylene polyamines in which amine nitrogen atoms on the polyamine backbone structure are replaced by guanidine groups provide a pH range extending into high pH values. These substances are useful as carri...
|
|
WO/2005/072246A2 |
The present invention discloses methods of use of facially amphiphilic polyaryl and polyarylalkynyl polymers and oligomers, including, but not limited to, pharmaceutical uses of the polymers and oligomers as antimicrobial agents and as a...
|
|
WO/2005/068488A1 |
The invention relates to a solid phase synthesis method for synthesising compounds of general formula (I) on a resin, wherein Z is, in particular a hydrogen atom or a fluorogenic or chromogenic group, m and p are, in particular equal to ...
|
|
WO/2005/051296A2 |
Novel fused ring dicationic anti-protozoan compounds. Representative protozoan species include but are not limited to Trypanosoma brucei rhodesiense (T.b.r) and Plasmodium faciparum. Prodrugs of these compounds can be used as an oral tre...
|
|
WO/2005/044787A1 |
Compounds of formula (I) and salts, solvates, and physiologically functional derivatives thereof, useful for the prophylaxis or treatment of a clinical condition for which a selective β2-adrenoreceptor agonist is indicated, for example ...
|
|
WO/2005/044810A1 |
&agr -, β-, and &gammad -amino acid derivatives of formula I are disclosed as selective GlyT2 inhibitors for the treatment of central nervous system (CNS) conditions such as muscle spasticity, tinnitus, epilepsy and neuropathic pain. Fo...
|
|
WO/2005/041925A2 |
Disclosed is controlled delivery of pharmaceutical agents and methods, dosage forms and devices therefore. In particular, formulation, dosage forms, methods and devices for enhanced absorption and controlled delivery drug compounds are d...
|
|
WO/2005/041924A2 |
Disclosed are substances, compositions, dosage forms and methods that comprise levodopa and/or carbidopa.
|
|
WO/2005/041923A1 |
A complex comprised of metformin and a transport moiety, such as a fatty acid, is described. The complex has an enhanced absorption in the gastrointestinal tract, particularly the lower gastrointestinal tract. The complex, and compositio...
|
|
WO/2005/041926A1 |
Disclosed are substances, compositions, dosage forms and methods relating to drugs including 3-aminopropyl-n-butyl-phosphinic acid; structural homologs thereof; 3-aminopropyl-n-butyl-phosphinic acid complexes; complexes that comprise str...
|
|
WO/2005/041928A1 |
A complex comprised of iron and a transport moiety, such as a fatty acid, is described. The complex has an enhanced absorption in the gastrointestinal tract, particularly the lower gastrointestinal tract. The complex, and compositions an...
|
|
WO/2005/041927A1 |
A complex comprised of gabapentin or pregabalin and a transport moiety, such as an alkyl sulfate, is described. The complex has an enhanced absorption in the gastrointestinal tract, particularly the lower gastrointestinal tract. The comp...
|
|
WO/2005/039494A2 |
The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including ...
|
|
WO/2005/040092A1 |
The present invention relates to a method for synthesis of an acrylamide derivative, starting with dissolving a salt of a nucleophilic amine in water to form an aqueous solution and desalting said solution with a base, comprising the fol...
|
|
WO/2005/037798A2 |
The present invention relates to novel compounds, pharmaceutical compositions comprising the same, use of said compounds for the manufacture of a medicament for treatment of pain and disorders related thereto as well as a method for trea...
|
|
WO/2005/033067A1 |
A novel compound of formula (I), a mutual salt of 1,2,6,7,8,8a-hexahydro-β,&dgr ,6-trihydroxy-2-methyl-8-[(2s)-2-methyl-1-oxobutoxy]-, (βR,&dgr R,1S,2S,6S,8S,8aR)- 1-naphthaleneheptanoic acid and N,N-dimethyl- imidodicarbonimidic diami...
|
|
WO/2005/024025A1 |
Novel polyene polyketides, their pharmaceutically acceptable salts, prodrugs and derivatives have been found to have antibiotic activity. Formula (I) One method for obtaining the compounds is by cultivation of Amycolatopsis orientalis AT...
|
|
WO/2005/016994A1 |
A method for preparing polyalkylenebiguanidine salt, which does not require a high-viscosity reactor and a toxic solvent, and is capable of producing various polyalkylenebiguanidine salt, is disclosed. The method comprises the steps of: ...
|
|
WO/2005/014528A1 |
Unique branched-chain lipid compounds are disclosed as selective COX-2 inhibitors, which are derivatives of a branched-chain fatty amine or a branched-chain fatty amide, or a pharmaceutically acceptable salt thereof. The compounds can be...
|
|
WO/2004/106288A2 |
The invention relates to salts containing guanidinium cations, to a method for their production and to their use as ionic liquids.
|
|
WO/2004/101502A1 |
This invention relates to a novel class of linear polyene polyketides, their pharmaceutically acceptable salts and derivatives, and to methods for their production. The compounds may be obtained by cultivation of Streptomyces melanospora...
|
|
WO/2004/094457A2 |
Disclosed herein are a chemical composition of 2-amino-6-[(2-amino-5 &lcub guanidine&rcub pentanoyl) amino] hexanoic acid (AAGPAHA) and a method of making it. The pharmaceutical composition includes AAGPAHA and a pharmaceutical excipient...
|
|
WO/2004/091613A2 |
Phenyl acetamide compounds are described, including compounds of Formula (I) or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R3-R6, R11, B, Y and W are set forth in the specification. The compounds of the inven...
|
|
WO/2004/087057A2 |
The present invention describes methods for inhibition angiogenesis in tissues using organic peptidomimetic v 3 antagonists, and particularly for inhibiting angiogenesis in inflamed tissues and in tumor tissues and metastases using thera...
|
|
WO/2004/077054A1 |
The present invention relates to methods for controlling the quality of binding measurements on microarrays, microarrays with control ligands and control ligands per se for carrying out said methods of quality control and methods for det...
|
|
WO/2004/073709A1 |
Compounds of formula (I) are antibacterial agents: wherein B represents R2R3N-, R2NH-C(=NR3)-, or R2NH-C(=NR3)-NR4- wherein each of R2, R3 and R4 represents hydrogen or a C1-C6 alkyl, phenyl, phenyl(C1-C6 alkyl)-, monocyclic heteroaryl, ...
|
|
WO2004048320B1 |
Biguanide and dihydrotriazine derivatives, preferably substituted asymmetrical imidodicarbonimidic diamides derived from hydroxylamines, and compositions containing biguanide and dihydrotriazine derivatives are disclosed. In addition, me...
|
|
WO/2004/065401A1 |
This invention relates to a new class of polyene polyketides, their pharmaceutically acceptable salts and derivatives, and to methods for obtaining the compounds. One method of obtaining these compounds is by cultivation of novel strains...
|
|
WO/2004/062601A2 |
Antibacterial compounds of formula (I) are provided: As well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infectio...
|
|
WO/2004/058691A1 |
This disclosure describes antifungal antibiotics designated Hygroscopene A, Hygroscopene B and Hygroscopene C to their production by fermentation, to methods for recovery and concentration from the crude solutions, to a process for purif...
|
|
WO/2004/058686A1 |
The present invention relates to compounds of formula (I); useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the betasecretase enzyme that are useful in the treatment of Alzheimer'...
|
|
WO/2004/054967A1 |
Formula (I) compounds are described where the groups are as identified in the text, and their use as medicines, particularly as anti-diabetes, serum glucose-lowering and anti-obesity agents. Said medicines are useful for the prophylaxis ...
|
|
WO/2004/031133A1 |
The invention pertains to a process for the synthesis of guanidine derivatives of Formula (I) wherein X is selected from OH, OM wherein M is an alkali or earth alkali metal ion, and NR1R2 wherein R1 and R2 are independently H, C1-C6 alky...
|
|
WO/2004/022528A2 |
The present invention relates to compounds of Formula (I), and salts solvates and hydrates thereof. The invention further relates to pharmaceutical compositions containing said compounds and methods of treating neurological, neuropsychia...
|
|
WO/2004/005422A1 |
An ultraviolet absorber which comprises an amidated guanidine derivative represented by the following general formula (I): (I) or a salt thereof. It has excellent solubility. The ultraviolet absorber can be incorporated into various cosm...
|
|
WO/2004/002944A1 |
The present invention provides compounds of Formula I, compositions and methods that are useful for treating viral infections and associated diseases, particularly HCV infections and associated diseases.
|
|
WO/2004/002940A1 |
The present invention provides compounds of Formula I, compositions and methods that are useful for treating viral infections and associated diseases, particularly HCV infections and associated diseases.
|
|
WO/2003/106410A1 |
Fluorinated cycloalkyl-derivatised benzoylguanidines of formula (I) are suitable for use as anti-arrhythmic medicaments comprising cardioprotective components for the prophylaxis and treatment of infarcts and also for the treatment of an...
|
|
WO/2003/103722A1 |
The invention provides MRI detectable species of formula (I): Dp-Sn-Nm, wherein D is a MRI detectable moiety; S is a spacer; N is a molecule of a nutrient or pseudo-nutrient; n is 0 or an integer; m is an integer and p is an integer. The...
|
|
WO/2003/099806A1 |
A novel creatine salt and the compositions containing same as active principle, such as dietary supplements, dietetic products, nutraceuticals, cosmetic and drugs, are disclosed.
|
|
WO/2003/095421A1 |
In the present specification we describe a new class of compounds, designed to modulate the ability of blood vessels to synthesize NO from L-arginine. In particular we have identified novel compounds which enhance the entry of L-arginine...
|
|
WO/2003/093302A2 |
A process is provided for the solid-phase synthesis of a peptide amide which comprises attaching a &agr -nitrogen protected C&agr -carboxamide amino acid to a solid support by its side chain, removing the &agr -nitrogen protecting group,...
|
|
WO/2003/091204A1 |
The present invention relates to novel compounds of formula (I), or a salt, solvate, or physiologically functional derivative thereof, to a process for their manufacture, to pharmaceutical compositions containing them, and to their use i...
|
|
WO/2003/086563A2 |
The present invention relates to fluorinated or paramagnetic anti-diabetes probes and methods for using the probes in diagnostic imaging processes and other imaging processes to determine physiological functions.
|
